China Pharma Inc. (CPHI)
China Pharma Statistics
Share Statistics
China Pharma has 3.26M shares outstanding. The number of shares has increased by 0.01% in one year.
| Shares Outstanding | 3.26M |
| Shares Change (YoY) | 0.01% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 17.09% |
| Shares Floating | 1.59M |
| Failed to Deliver (FTD) Shares | 30.46K |
| FTD / Avg. Volume | 29.59% |
Short Selling Information
The latest short interest is 66.43K, so 0.35% of the outstanding shares have been sold short.
| Short Interest | 66.43K |
| Short % of Shares Out | 0.35% |
| Short % of Float | 0.51% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -8.59 and the forward PE ratio is null. China Pharma's PEG ratio is 0.12.
| PE Ratio | -8.59 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for China Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.65, with a Debt / Equity ratio of 0.
| Current Ratio | 0.65 |
| Quick Ratio | 0.2 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -29770766.84 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $20.22B |
| Profits Per Employee | $-21.14K |
| Employee Count | 224 |
| Asset Turnover | 0.3 |
| Inventory Turnover | 2.87 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -35.1% in the last 52 weeks. The beta is 0.77, so China Pharma's price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | -35.1% |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 2.16 |
| Relative Strength Index (RSI) | 50.2 |
| Average Volume (20 Days) | 102.94K |
Income Statement
In the last 12 months, China Pharma had revenue of 4,528.9B and earned -4.74M in profits. Earnings per share was -0.27.
| Revenue | 4,528.9B |
| Gross Profit | -1,985.6B |
| Operating Income | -4,588.9B |
| Net Income | -4.74M |
| EBITDA | -4,588.9B |
| EBIT | -4,890.5B |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
The company has 626.88K in cash and 3.59M in debt, giving a net cash position of -2.96M.
| Cash & Cash Equivalents | 626.88K |
| Total Debt | 3.59M |
| Net Cash | -2.96M |
| Retained Earnings | -44,026.7B |
| Total Assets | 14.89M |
| Working Capital | -1.75M |
Cash Flow
In the last 12 months, operating cash flow was -466.36B and capital expenditures -291.72K, giving a free cash flow of -504.77B.
| Operating Cash Flow | -466.36B |
| Capital Expenditures | -291.72K |
| Free Cash Flow | -504.77B |
| FCF Per Share | -28904.09 |
Margins
Gross margin is -43.84%, with operating and profit margins of -101.32% and 0%.
| Gross Margin | -43.84% |
| Operating Margin | -101.32% |
| Pretax Margin | -104.58% |
| Profit Margin | n/a |
| EBITDA Margin | -101.32% |
| EBIT Margin | -101.32% |
| FCF Margin | -11.15% |
Dividends & Yields
CPHI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CPHI.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 15, 2025. It was a backward split with a ratio of 1:10.
| Last Split Date | Apr 15, 2025 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -4.57 |
| Piotroski F-Score | 2 |